Sanofi and Novo Nordisk press ahead with US insulin prices rises - (Financial Times via NewsPoints Desk)

  • Novo Nordisk and Sanofi unveiled price increases on insulin earlier this month in the US despite increasing political pressure, Financial Times reported Thursday.

  • Specifically, Sanofi increased the prices of Apidra, Lantus and Toujeo SoloSTAR by 4.4 percent to 5.2 percent earlier this month, while Novo Nordisk boosted the prices of Tresiba and Levemir by nearly 5 percent on January 8.

  • "Diabetic patients who require insulin to remain healthy, and in some cases stay alive, were dealt a blow with the latest price increases," remarked RX Savings Solutions CEO Michael Rea.

  • The price increases come after FDA Commissioner Scott Gottlieb said last month that "limited competition" for insulin-based treatments had kept prices "artificially high," causing some patients to ration their medicines.

  • Commenting on the news, Sanofi stated that the costs of its drugs, after including discounts, had declined for three straight years and that its price increases were less than the "medical inflation rate."

  • Meanwhile, Novo Nordisk noted that the price hikes were in line with the its promise to restrain price increases to less than 10 percent annually.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

  •  

To read more NewsPoints articles, click here.